Compare · DMAC vs JNJ
DMAC vs JNJ
Side-by-side comparison of DiaMedica Therapeutics Inc. (DMAC) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DMAC and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $556.77B, about 1754.3x DMAC ($317.4M).
- Over the past year, DMAC is up 61.6% and JNJ is up 52.9% - DMAC leads by 8.7 points.
- Both names hit the wire about 10 times in the past 4 weeks.
- JNJ has more recent analyst coverage (25 ratings vs 6 for DMAC).
- Company
- DiaMedica Therapeutics Inc.
- Johnson & Johnson
- Price
- $5.90+1.37%
- $231.34+1.31%
- Market cap
- $317.4M
- $556.77B
- 1M return
- +2.97%
- +0.90%
- 1Y return
- +61.64%
- +52.92%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 10
- 10
- Recent ratings
- 6
- 25
DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest DMAC
- DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
- SEC Form 4 filed by Director Giuffre Randall Michael
- SEC Form 4 filed by Director Kuntz Richard
- SEC Form 4 filed by Director O'Connor Daniel J.
- SEC Form 4 filed by Director Lewis Tanya
- SEC Form 4 filed by Director Semba Charles Pauling
- SEC Form 4 filed by Director Parsons James T.
- SEC Form 4 filed by President & CEO Pauls Dietrich John
- SEC Form 4 filed by CFO & Secretary Kellen Scott
- SEC Form 4 filed by Chief Medical Officer Krop Julie
Latest JNJ
- Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
- New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
- EVP, Chief TO and Risk Officer Wengel Kathryn E exercised 10,000 shares at a strike of $115.67 and sold $2,411,500 worth of shares (10,000 units at $241.15) (SEC Form 4)
- SEC Form 4 filed by Director Woods Eugene A.
- Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
- IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
- Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm